Trial Profile
A retrospective study analysing effectiveness of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2018
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Oct 2018 New trial record